miR-372/3 Inhibitor; Neomycin-S

Biochem/physiol Actions

Reversible: yes

Primary TargetmiRNA-272/273

General description

A cell-permeable neomycin derived artificial nucleobase conjugate that inhibits the production of oncogenic miRNAs 372 (IC₅₀ = 2.4 µM; K_d = 16 nM) and 373 (IC₅₀ = 5.13 µM K_d = 21.4 nM) by directly binding to their precursors pre-miRNAs and interrupts their processing by Dicer. In comparison, neomycin does not affect these miRNAs (IC₅₀ = 125 µM; K_d = 7.4 µM). Shown to depress proliferation of AGS gastric cancer cells expressing miRNA 372 and 373. However, it has no effect on MKN74 gastric epithelial cells that do not express miRNA 372 and 373. Reduced levels of miRNA 372 results in de-repression of their targets, such as the cell cycle regulator large tumor suppressor homologue 2 (LATS2).Please note that the molecular weight for this compound is batch-specific due to variable water content.

A cell-permeable neomycin derived artificial nucleobase conjugate that inhibits the production of oncogenic miRNAs 372 (IC₅₀ = 2.4 µM; K_d = 16 nM) and 373 (IC₅₀ = 5.13 µM K_d = 21.4 nM) by directly binding to their precursors pre-miRNAs and interrupts their processing by Dicer. In comparison, neomycin does not affect these miRNAs (IC₅₀ = 125 µM; K_d = 7.4 µM). Shown to depress proliferation of AGS gastric cancer cells expressing miRNA 372 and 373. However, it has no effect on MKN74 gastric epithelial cells that do not express miRNA 372 and 373. Reduced levels of miRNA 372 results in de-repression of their targets, such as the cell cycle regulator large tumor suppressor homologue 2 (LATS2).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Vo, D.D., et al. 2014. ACS Chem. Biol.9, 711.

Packaging

Packaged under inert gas

2 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-2-°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)